Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
SepsisIntoxication; Septic
Interventions
DRUG

Rheosorbilact®

Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.

DRUG

Ringer lactate

Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.

Trial Locations (13)

21029

Central District Clinical Hospital, Vinnitsa

29000

Khmelnytskyi Regional Clinical Hospital, Khmelnytskyi

49005

Dnipro's Medical Academy of Ministry of Health of Ukraine, Dnipro

61018

Zaicev's Institute of general and urgent surgery NMA Ukraine, Kharkiv

69065

Zaporizka Medical Academy of postgraduate education, Zaporizkyi Clinical Hospital N9, Zaporizhzhya

Unknown

"Unimedi Adjara LLC", Batumi

Kutaisi Referral Hospital, Kutaisi

Hospital of the Medical Center of the Administration of the President of the Republic of Kazakhstan, Astana

Institute of Ambulance, Chisinau

"Municipal Clinical Hospital Sfinta Treime", Chisinau

Republican Clinical Hospital, Chisinau

"HSEE of Ukraine Ukrainian Medical Stomatological Academy; Poltava Central District Hospital", Poltava

Republic Centre of Ambulance, Tashkent

All Listed Sponsors
lead

Yuria-Pharm

INDUSTRY

NCT03764085 - Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis. | Biotech Hunter | Biotech Hunter